B01 SynMiCdb: The database for synonymous mutations in cancer identifies recurrent changes in conserved loci paralleling missense mutations. Karine Boulay, DKFZ, Heidelberg, Germany.

B02 A regulatory role for codon bias in KRAS-driven tumor progression and therapeutic resistance. Erin Kaltenbrun, Duke University, Durham, NC, United States.

B03 A whole genome screening platform to identify genes that overcome the poor translation of KRAS. Jackson Peterson, Duke University, Durham, NC, United States.

B04 Anti-HER2 therapies activate the PKR-eIF2α serine 51 arm to promote tumor suppression in breast cancer. Antonis Koromilas, Lady Davis Institute-McGill University, Montreal, Quebec, Canada.

B05 Characterization of the pre-ribosomal complex, which mediates the p53 Impaired Ribosome Biogenesis Checkpoint (IRBC). Sandra Menoyo, Laboratory of Metabolism and Cancer, Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

B06 Translational control of mitochondria through mTORC1/4E-BP signaling pathway. Masahiro Morita, McGill University, Montreal, QC, Canada.

B07 Loss of APC induces a dependence on elevated eIF2B5 function in colorectal cancer. Stefanie Peter, University Hospital Wuerzburg, Wuerzburg, Germany.


B09 hnRNPA1 is a regulator of UNR IRES activity. Tobias Schmid, Institute of Biochemistry 1, Goethe-University, Frankfurt, Germany.

B10 Inhibiting eIF4F-mediated adaptive translatome reprogramming is a salvage strategy for targeted melanoma therapy. Shensi Shen, Gustave Roussy Cancer Campus, Villejuif, France.

B11 Oncogenic KRAS regulates 4E-BP1, a repressor of cap-dependent translation, independently of growth factor activity. Jillian Silva, University of California, San Francisco, San Francisco, CA, United States.

B12 Expression of Integrated Stress Response proteins during the progression of UVB-induced squamous cell carcinoma. Dan Spandau, Indiana University School of Medicine, Indianapolis, IN, United States.

B13 EGF/Ras/Erk signalling controls growth and proliferation through regulation of tRNA synthesis. Shrivanii Sriskanthadevan-Pirahas, University of Calgary, Calgary, AB, Canada.

B14 Evidence that Tma20 and Tma22 do not promote translation re-initiation in yeast. Victoria Torrance, Newcastle University, Newcastle-Upon-Tyne, United Kingdom.
Poster Session B  
Saturday, October 29, 2016  
5:00 p.m.–7:00 p.m.  
Pacific A–G

B15 Non-serine synthesis enzymatic function of phosphoserine aminotransferase 1 binds target proteins to promote metastatic progression in lung cancer. Hsing-Fang Tsai, Genomics Research Center, Academia Sinica, Taipei, Taiwan.

B16 Cytoplasmic RNA stress granules: A putative translational mechanism of mTOR regulation in glioblastoma. Adrienne Weeks, Dalhousie University, Halifax, NS, Canada.

B17 Precise statistical algorithms reveal novel fusions and potential impacts of fusions on translational regulation. Julia Salzman, Stanford University Department of Biochemistry, Palo Alto, CA, United States.

B18 Discovery of the mammalian ribo-interactome connects metabolism enzymes with specialized ER-ribosomes. Deniz Simsek, Stanford University, Stanford, CA, United States.

B20 Targeting eIF2α phosphorylation for cancer therapy. Bertal Aktas, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

B21 Novel pateamine A analogs to target pro-survival proteins in chronic lymphocytic leukemia. Rong Chen, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B22 Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors together with AR antagonists in advanced prostate cancer. Leandro D’Abronzo, University of California Davis, Davis, CA, United States.

B23 Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer. Luc Furic, Monash University, Clayton, Vic, Australia.


B25 Discovery of molecular probes inhibiting La:RNA interactions in cancer cells. Tilman Heise, Medical University of South Carolina (MUSC), Charleston, SC, United States.

B26 A novel naturally-derived withalonglide synergizes with cisplatin to block self-renewal, migration, and EMT transition to enhance apoptosis via targeting of translational initiation. Chitra Subramanian, University of Michigan, Ann Arbor, MI, United States.

B27 Morphological changes, cadherin switching, and growth suppression in pancreatic cancer by GALNT6 knockdown. Yunus Tarhan, University of Chicago, Chicago, IL, United States.

B28 Discovery of 2-acetylpyridine-[N-(3-hydroxy-2-naphthoyl)]hydrazone analogs as glycine N-methyltransferase (GNMT) inducers for the treatment of hepatocellular carcinoma (HCC). Cherng-Chyi Tzeng, Kaohsiung Medical University, Kaohsiung City, Taiwan.
B29 eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade. Kevin Webster, eFFECTOR Therapeutics, San Diego, CA, United States.

B30 The RNA-binding protein LARP1 is a cancer therapeutic target. Sarah Blagden, Department of Oncology, University of Oxford, Oxford, Oxfordshire, United Kingdom.

B31 NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Iok In Christine Chio, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.


B33 Translational control pathways form a molecular hub that regulates tamoxifen resistance in ER+ breast cancer. Phillip Geter, New York University School of Medicine, New York, NY, United States.

B34 Inhibitor of DNA binding (Iid) regulates glioma infiltration on myelin tracts by suppressing Nogo receptor 1. JunHee Hong, Specific Organs Cancer Branch, National Cancer Center, Goyang-Si, Gyeonggi-Do, Korea, Republic Of.

B35 Defining changes in the cells' translation profiles in response to cancer therapies that target the ribosome. Eric Kusnadi, Peter MacCallum Cancer Center, Melbourne, Vic, Australia.

B36 Translational control of human colon tumor cell survival. Eyerusalem Lemma, University of Nebraska Medical Center, Omaha, NE, United States.

B37 Estrogen receptor alpha coordinates homeostatic gene expression programs via translational buffering. Julie Lorent, Karolinska Institute, Stockholm, Sweden.

B38 Tumor heterogeneity evaluation in glioblastomas using microarray of polysomal mRNAs. Fernanda Lupinacci, AC Camargo Cancer Center, Sao Paulo, Brazil.

B39 Asparagine drives translational adaptation of cancer cells to glutamine deficit. Natalya Pavlova, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B40 Intratumor heterogeneity in lung adenocarcinoma: Beyond genetics. Santiago RamonyCajal, Hospital Universitary Vall'Hebron, Barcelona, Barcelona, Spain.

B41 Specific targeting of eIF4A mRNA helicase paralogs in lung cancer. Farheen Raza, Medical Research Council Toxicology Unit, Leicester, United Kingdom.

B42 Combination of liquid chromatography-surface enhanced Raman spectroscopy and liquid chromatography-mass spectrometry to identify SUMOylated proteins due to nutrient restriction in colorectal cancer. Monica Schroll, University of Notre Dame, Notre Dame, IN, United States.
B43 Global upregulation of ribosomal protein gene pathway in normal cerebellar progenitor development and in pathogenesis of sonic hedgehog subtype medulloblastomas. Issei Shimada, UT Southwestern Medical Center, Dallas, TX, United States.

B44 Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells. Chara Stavraka, Imperial College, London, United Kingdom.

B45 Insights into the anti-prostate cancer activity of pterostilbene. Mai Tolba, Ain Shams University, Cairo, Non-Us/Non-Canadian, Egypt.

B46 Activation of TWIST1 by COL11A1 decreases cell sensitivity to paclitaxel by modulating NFκB-mediated Iκκβ expression expression. Yi-Hui Wu, National Cheng Kung University, Tainan, Taiwan.

B47 A novel combination of Biochanin-A / 5-Fluorouracil against colon cancer: Impact on Wnt/beta-catenin signaling. Mai Tolba, Ain Shams University, Cairo, Egypt.

B48 Oncogenic Ras reprograms metabolism by suppressing TXNIP translation. Zhizhou Ye, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.